Bristol-Myers Squibb (BMY) | Stock Overview & Key Data
Bristol-Myers Squibb Performance Comparison
Stock Range
Today's Range
Low: $43.57
High: $44.46
on August 1, 2025
52 Week Range
Low: $42.96
High: $63.33
on July 31, 2025
on March 11, 2025
All-Time High: $81.44 on November 28, 2022
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$90.0B
EPS
2.49
P/E Ratio (TTM)
17.76
Forward P/E
6.29
P/B Ratio
5.16
PEG Ratio
6.29
Div. Yield
N/A
ROE
29.32%
Beta
0.371
Debt to Equity
291.55
Financial Highlights
Profitability
Gross Margin
72.52%
Operating Margin
33.66%
Profit Margin
10.58%
Returns and Earnings
Return on Assets (TTM)
8.34%
Return on Equity (TTM)
29.32%
EBITDA
$18.3B
Net Income (TTM)
$5.0B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$23.51
Quarterly Revenue Growth (YoY)
0.60%
Quarterly Earnings Growth (YoY)
-22.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb BMY | 90.03B Large-cap | -8.67% | -6.90% | -10.84% | -26.22% | -22.12% | -9.31% | -38.67% | -27.52% |
| Eli Lilly and LLY | 684.37B Mega-cap | -6.20% | -1.75% | -4.00% | -5.94% | -2.02% | -5.24% | 153.00% | 398.48% |
| Johnson & Johnson JNJ | 402.99B Mega-cap | -0.58% | 7.32% | 8.33% | 10.18% | 16.19% | 1.94% | -2.21% | 12.60% |
| Merck & Co MRK | 199.10B Large-cap | -6.40% | -3.08% | -4.77% | -20.54% | -20.05% | -31.17% | -9.29% | 2.56% |
| Amgen AMGN | 159.63B Large-cap | -3.16% | 2.19% | 4.62% | 2.77% | 14.50% | -11.11% | 20.56% | 23.35% |
| Gilead Sciences GILD | 140.79B Large-cap | -2.60% | 1.30% | 9.62% | 15.04% | 23.18% | 47.43% | 85.27% | 63.20% |
Ownership & Short Interest
Insider Ownership
0.08%
Institutional Ownership
81.93%
Shares Short
38M
Short Ratio
2.58
Short % of Shares Outstanding
1.89%
Average 10-Day Volume
15M
Average 90-Day Volume
15M
Bristol-Myers Squibb Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Bristol-Myers Squibb would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BMY's 52-week high and low?
- In the last 52 weeks, Bristol-Myers Squibb reached a high of $63.33 (on March 11, 2025) and a low of $42.96 (on July 31, 2025).
- What is the market cap and P/E ratio for BMY?
- Curious about Bristol-Myers Squibb's size and valuation? Its market capitalization stands at 90.03B. When it comes to valuation, the P/E ratio (trailing twelve months) is 17.76, and the forward P/E (looking ahead) is 6.29.
- Does BMY pay dividends? If so, what's the yield?
- As for dividends, Bristol-Myers Squibb isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Bristol-Myers Squibb's main competitors or similar companies to consider before investing?
When looking at Bristol-Myers Squibb, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY684.37B Healthcare Drug Manufacturers - General -5.24% 153.00% Johnson & Johnson
JNJ402.99B Healthcare Drug Manufacturers - General 1.94% -2.21% Merck & Co
MRK199.10B Healthcare Drug Manufacturers - General -31.17% -9.29% Amgen
AMGN159.63B Healthcare Drug Manufacturers - General -11.11% 20.56% Gilead Sciences
GILD140.79B Healthcare Drug Manufacturers - General 47.43% 85.27% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bristol-Myers Squibb Company? (e.g., ROE, Debt/Equity)
- To get a sense of Bristol-Myers Squibb's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 29.32%, the Debt to Equity ratio from the most recent quarter is 291.55, and its Gross Profit Margin stands at 72.52%.
- What is the recent revenue and earnings growth for BMY?
- Looking at Bristol-Myers Squibb's growth, its revenue over the trailing twelve months (TTM) was $48B. Compared to the same quarter last year (YoY), quarterly revenue grew by 0.60%, and quarterly earnings saw a YoY growth of -22.00%.
- How much of BMY stock is held by insiders and institutions?
- Wondering who owns Bristol-Myers Squibb stock? Company insiders (like executives and directors) hold about 0.08% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 81.93%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.